American Society of Hematology

Figure 2.

$Figure 2. Blockade of p53-MDM2 binding induces apoptosis in primary AML cells. (A) Primary AML cells from patients 1 to 5 were incubated with the indicated concentrations of Nutlin-3a (active enantiomer, ▪) or -3b (less active enantiomer, ▦) for 72 hours, and the annexin V–positive fractions were measured by flow cytometry. □ represents DMSO-treated controls. (B) Primary AML cells from patient 8 were treated with the indicated concentrations of Nutlin-3a, and flow cytometry analysis using CD34-PE and annexin V–FITC antibodies was performed at the indicated times.$

Blockade of p53-MDM2 binding induces apoptosis in primary AML cells. (A) Primary AML cells from patients 1 to 5 were incubated with the indicated concentrations of Nutlin-3a (active enantiomer, ▪) or -3b (less active enantiomer, ▦) for 72 hours, and the annexin V–positive fractions were measured by flow cytometry. □ represents DMSO-treated controls. (B) Primary AML cells from patient 8 were treated with the indicated concentrations of Nutlin-3a, and flow cytometry analysis using CD34-PE and annexin V–FITC antibodies was performed at the indicated times.

This Feature Is Available To Subscribers Only